NCT01814800View on ClinicalTrials.gov

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Primary Immune Deficiency Disorder
Interventions
BIOLOGICAL

RI-002

Immune Globulin Intravenous (IGIV)

Trial Locations (9)

10029

Mount Sinai School of Medicine, New York

30342

Family Allergy Center, PC, Atlanta

33408

Allergy Associates of the Palm Beaches, P.A., North Palm Beach

46617

The South Bend Clinic, LLP, South Bend

68124

Asthma & Immunology Associates, Omaha

75230

Dallas Immunology Research, Dallas

75231

AARA Research Center, Dallas

77030

Baylor Texas Children's Hospital, Houston

80112

IMMUNOe Health Centers, Cenntennial

Sponsors
All Listed Sponsors
lead

ADMA Biologics, Inc.

INDUSTRY